Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib plus Capecitabine in Trastuzumab-resistant HER2+ Advanced Breast Cancer
NCT04001621Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jun 2019
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in HER2-positive breast cancer, sponsored by Fudan University. Primary endpoint: Progression Free Survival at 12 months. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04001621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04001621.